Business Wire

NY-ESTÉE-LAUDER

30.9.2022 12:46:43 CEST | Business Wire | Press release

Share
The Estée Lauder Companies Launches 2022 Breast Cancer Campaign to Honor 30th Anniversary and Positively Impact the Global Breast Cancer Community

In the 30 years since Evelyn H. Lauder launched The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) and co-created the Pink Ribbon in 1992, The Campaign’s mission to help create a breast cancer-free world for all has remained steadfast. The Estée Lauder Companies (ELC) has a long-standing commitment to helping women and girls achieve their highest potential. As ELC’s largest corporate social impact program, The Campaign is a cornerstone of ELC’s social investments in women’s advancement and health, uniting people everywhere to positively impact the global breast cancer community. As breast cancer is the most commonly diagnosed cancer in the world,1 ELC's continued commitment to improving the lives of all those touched by the disease remains unwavering.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005040/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Estée Lauder Companies Launches 2022 Breast Cancer Campaign (Graphic: Business Wire)

Together, The Estée Lauder Companies’ Breast Cancer Campaign and The Estée Lauder Companies Charitable Foundation (ELCCF) have funded more than $108 million globally for lifesaving research, education and medical services, with more than $86 million funding medical research grants through the Breast Cancer Research Foundation (BCRF). Founded in 1993 by Evelyn H. Lauder, BCRF is dedicated to advancing the world’s most promising research. ELC’s commitment to breast cancer research, spanning three decades, has been transformative. In partnership with BCRF, The Campaign has helped fuel research across the entire spectrum of the disease—from tumor biology, lifestyle and genetics, survivorship, treatment, and metastasis—making an indelible mark in the diagnosis, care, and prevention of breast cancer. In addition, The Campaign supports more than 60 organizations worldwide, facilitating real change aligned to the diverse needs of local communities.

Deaths from breast cancer have declined 42% in the U.S. since the late 1980s.2 However, that progress has not been experienced equally and certain populations are at higher risk for adverse breast cancer outcomes. At every age, Black women in the U.S. are more likely to die from breast cancer than any other race or ethnic group, and mortality rates remain 41% higher than in white women, despite lower incidence.3 The Campaign has and continues to support BCRF-funded research that identifies and addresses disparities that exist across the entire breast cancer landscape. ELCCF’s $15 million donation over five years will fund a new BCRF research initiative to accelerate The Campaign’s goal of reducing breast cancer disparities and improving outcomes. This comprehensive study of the intersection of social determinants of health, comorbidities, and the biology of breast cancer in Black women has the potential to significantly impact breast cancer disparities globally. It will help advance personalized breast cancer health care across prevention, diagnosis, and treatment for those at most risk of dying from the disease, and has the potential to be groundbreaking for the global breast cancer community.

William P. Lauder, Executive Chairman of The Estée Lauder Companies Inc. shared, “The potential impact that this BCRF initiative will have in accelerating a crucial area of research cannot be overstated, as we collectively work towards a more equitable future for all. I know my mother, Evelyn Lauder, would be so proud of the advancements we have made through research, education, access to care and our commitment to help end breast cancer.”

In the past 30 years globally, The Campaign has:

  • Funded medical research and fellowships, as well as medical resources, services and centers, including access to mammograms and screenings for vulnerable groups with limited access to healthcare.
  • Advanced conversations on the importance of breast health education and early detection by facilitating discussions between the breast cancer community, medical experts and key opinion leaders.
  • Supported therapy and counseling programs to help improve the lives of people with breast cancer and their families.
  • Distributed educational materials and more than 180 million Pink Ribbons to spread awareness.

“The Estée Lauder Companies’ success is deeply rooted in living our shared values. Reflecting on the last 30 years, the incredible progress made by The Breast Cancer Campaign has had a lasting impact on our global community. As an authentic cornerstone of our commitments, The Campaign has been supported by our employees, consumers and partners worldwide. Today, it continues to inspire action in people everywhere. As a Beauty Inspired, Values Driven company, we look forward to the future and are committed to advancing positive change for all of those touched by this disease,” said Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies Inc.

The Campaign will take the following actions aligned to its mission for its 30th Anniversary:

  • Double-down on The Campaign’s efforts to reduce breast cancer disparities and improve health outcomes.
  • Mobilize ELC’s passionate employees to unite in action and support more than 60 organizations worldwide.
  • Show support through 18 of ELC’s brands: Estée Lauder, Clinique, Lab Series, Origins, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, AERIN Beauty, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, and Dr.Jart+. Each will donate to BCRF and/or local cancer-focused organizations around the world, with brand participation varying by market.
  • Convene breast cancer thought leaders and advocates to advance education and share important messages about the disease.
  • Drive additional donations to BCRF through ELCompanies.com/BreastCancerCampaign and various points of engagement.
  • Accelerate communications on social media including TikTok and various Meta platforms to foster awareness, fundraising and engagement, including new calls-to-action.
  • Unveil a new series of global stories demonstrating the diversity of the disease.
  • Continue The Campaign’s tradition of illuminating buildings, monuments and landmarks around the world in glowing pink lights to raise awareness of breast health, including the Empire State Building, New York City; the Eiffel Tower, Paris; LOTTE WORLD TOWER, Seoul.
  • Continue producing and distributing informative materials and Pink Ribbons worldwide.

As long as breast cancer remains a life-threatening disease, The Estée Lauder Companies’ commitment to the meaningful work that must continue will not waiver. It’s #TimeToEndBreastCancer.

ABOUT THE ESTÉE LAUDER COMPANIES INC.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

ELC-C
ELC-I

_____________________________
1 World Health Organization
2 American Cancer Society® Facts and Figures 2021-2022
3 American Cancer Society® Key Statistics for Breast Cancer

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220930005040/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 09:00:00 CEST | Press release

Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu

OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 09:00:00 CEST | Press release

Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign

LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 09:00:00 CEST | Press release

Expanded availability of LogicMonitor within Deutsche Telekom’s managed services portfolio follows successful operational use in the UKSelect outcomes include reduced reporting times and proactive incident preventionExpansion extends across DACH, Benelux, and the Nordics LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Throug

Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 09:00:00 CEST | Press release

ZH9 is very well tolerated with a favourable safety profile, and no dose-limiting toxicities or Grade ≥3 drug-related adverse events reported.ZH9 demonstrates 91% freedom-from-relapse in NMIBC patients who have reached study end.Company plans to run a larger phase 2 study across a range of patient populations spanning intermediate risk and high risk including CIS. Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early a

VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer18.5.2026 08:00:00 CEST | Press release

Endotronix co-founder and former CEO joins VahatiCor as the company advances the A-FLUX Reducer System® and the SERRA-I early feasibility study VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/ VahatiCor CEO, Harry D. Rowland, Ph.D. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed o

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye